Corbus Pharmaceuticals announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). Topline data showed no significant…
Sino-American biotech Connect Biopharma has collected $115 million in Series C financing led by a new investor, RA Capital Management plus new investors, including Lilly…
CymaBay Therapeutics reported positive top-line results from the ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment…
Immunic Therapeutics reported positive top-line data from the phase 2 EMPhASIS trial evaluating IMU-838 versus placebo in patients with relapsing relapsing-remitting multiple sclerosis (RRMS). The…
Indiana University School of Medicine announced today a strategic research agreement with Eli Lilly and Company designed to, in the longer run, benefit people suffering…
Francesco Boin, MD, a nationally recognized rheumatology expert, has been appointed the director of the division of Rheumatology and director of the new Scleroderma Program…
Celltrion Healthcare is partnering with the University of Oxford and University Hospitals Birmingham to study the use of CT-P13 (biosimilar infliximab) to accelerate COVID-19 recovery.…
A Georgia State University professor received a five-year, $1.95 million federal grant to study the causes of autoimmunity in the human body. Dr. Leszek Ignatowicz…
Ocugen announced the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is…
SOBI announced that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary hemophagocytic lymphohistiocytosis (HLH)…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
